⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20372615 | 0.65 | — | — | |
| SCHEMBL8074357 | 0.65 | — | — | |
| SCHEMBL8019114 | 0.61 | — | — | |
| SCHEMBL4685684 | 0.61 | — | — | |
| SCHEMBL15797702 | 0.55 | CA2 (0.36) | — | |
| Ammonia Solution, Strong SCHEMBL5697195 | 0.55 | — | — | |
| SCHEMBL11854072 | 0.55 | — | — | |
| SCHEMBL2069806 | 0.50 | — | — | |
| SCHEMBL324377 | 0.50 | — | — | |
| SCHEMBL19521845 | 0.50 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026099847-A1 | SYNTHESIS OF CYANO-ANTHRANILIC ACID | ADAMA MAKHTESHIM LTD. (IL) | 2026-05-15 | — | — | WO | claimed |
| CN-100540068-C | Cement formulation, bone substitute material, and method of forming cement formulation | KYPHON INC (US) | 2009-09-16 | — | — | CN | claimed |
| CN-1849145-A | Formulation for a cement preparation as bone substitute | KYPHON INC (US) | 2006-10-18 | — | — | CN | claimed |
| WO-2026099847-A1 | SYNTHESIS OF CYANO-ANTHRANILIC ACID | ADAMA MAKHTESHIM LTD. (IL) | 2026-05-15 | — | — | WO | disclosed |
| WO-2024038436-A1 | PROCESS FOR PREPARING CYANTRANILIPROLE VIA AMINO-CYANO-BENZENE DERIVATIVE | ADAMA MAKHTESHIM LTD. (IL) | 2024-02-22 | — | — | WO | disclosed |
| CN-106536562-B | Combination of lenalidomide or pomalidomide and an interferon alpha construct detoxified by an anti-CD 38 antibody, and uses thereof | 泰华制药澳大利亚公司 | 2023-04-14 | — | — | CN | disclosed |
| WO-2018094293-A1 | A KIT FOR DETERMINING THE ABSOLUTE CONFIGURATION OF ALCOHOLS USING A COMPETING ENANTIOSELECTIVE CONVERSION APPROACH | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-05-24 | — | — | WO | disclosed |
| WO-2017066583-A1 | A NANOMATERIAL COMPLEX COMPRISING GRAPHENE OXIDE ASSOCIATED WITH A THERAPEUTIC AGENT AND METHODS OF USE | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2017-04-20 | — | — | WO | disclosed |
| EP-2154958-A1 | TREATMENT OF CARDIOVASCULAR DISEASE AND DYSLIPIDEMIA USING SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITORS AND SPLA2 INHIBITOR COMBINATION THERAPIES | Anthera Pharmaceuticals, Inc. (US) | 2010-02-24 | — | — | EP | disclosed |
| CN-100540068-C | Cement formulation, bone substitute material, and method of forming cement formulation | KYPHON INC (US) | 2009-09-16 | — | — | CN | disclosed |
| WO-2008137803-A1 | TREATMENT OF CARDIOVASCULAR DISEASE AND DYSLIPIDEMIA USING SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITORS AND SPLA2 INHIBITOR COMBINATION THERAPIES | ANTHERA PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | WO | disclosed |
| US-20080207505-A1 | Bna Conjugates and Methods of Use | JAMES KENNETH D | 2008-08-28 | — | — | US | disclosed |
| CN-1849145-A | Formulation for a cement preparation as bone substitute | KYPHON INC (US) | 2006-10-18 | — | — | CN | disclosed |
| WO-1995021822-A1 | PYRIDINIUM COMPOUNDS | GEORGIA TECH RESEARCH CORPORATION (US) | 1995-08-17 | — | — | WO | disclosed |
| EP-0643697-A4 | QUATERNARY PYRIDINIUM COMPOUNDS. | — | 1995-04-12 | — | — | EP | disclosed |
| EP-0643697-A1 | QUATERNARY PYRIDINIUM COMPOUNDS | GEORGIA TECH RESEARCH CORPORATION (US) | 1995-03-22 | — | — | EP | disclosed |
| WO-1993024459-A1 | QUATERNARY PYRIDINIUM COMPOUNDS | GEORGIA TECH RESEARCH CORPORATION (US) | 1993-12-09 | — | — | WO | disclosed |